|
KMID : 0360220140550020209
|
|
Journal of the Korean Ophthalmological Society
2014 Volume.55 No. 2 p.209 ~ p.215
|
|
|
Effects of Macular Ischemia and Early Treatment on Visual Outcome in Branch Retinal Vein Occlusion
|
|
Sea Kyung-Hoon
Yang Ji-Ho
Yu Seung-Young
Kwak Hyung-Woo
|
|
|
Abstract
|
|
|
Purpose:To evaluate the effects of macular ischemia and early treatment on the visual outcomes of patients with branch retinal vein occlusion (BRVO).
Methods:This study retrospectively reviewed the records of 42 patients who were treated with an intravitreal bevacizumab injection for BRVO, repeated 3 times at 6-week intervals and were whose data available for a follow-up period of at least 4 years. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) results before treatment and at 6, 12, 24, 36 and 48 months after the 3 serial injections, were measured. We assessed macular ischemia, time to the first treatment, and the relationship of these with BCVA.
Results: Mean BCVA (log MAR) was significantly improved from 0.67 ± 0.43 at baseline to 0.30 ± 0.30 at 48 months (p < 0.001). Four years after treatment, mean BCVA in the macular non-ischemic group was better than in the ischemic group, but this relationship did not hold for mean change in BCVA. There was a statistically significant (p < 0.05) difference between the early (≤6 weeks) and late (>6 weeks) treatment groups in BCVA and mean change in BCVA after 48 months. There was statistically significant (p < 0.05) difference between the early (≤6 weeks) and late (>6 weeks) treatment groups with macular ischemia in BCVA after 48 months.
Conclusions: In patients with BRVO, a significant visual improvement was maintained after intravitreal bevacizumab injections, despite the presence of macular ischemia. Early treatment (within 6 weeks) is more effective for maintaining and improving visual acuity. Similar results in the macular ischemia group confirmed the importance of early treatment.
|
|
|
KEYWORD
|
|
|
Bevacizumab, Branch retinal vein occlusion, Early treatment, Four-year results, Macular ischemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|